Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-08-30

AUTHORS

Danielle J. Vugts, Chris Klaver, Claudia Sewing, Alex J. Poot, Kevin Adamzek, Seraina Huegli, Cristina Mari, Gerard W. M. Visser, Ibai E. Valverde, Gilles Gasser, Thomas L. Mindt, Guus A. M. S. van Dongen

ABSTRACT

PurposeAll clinical 89Zr-immuno-PET studies are currently performed with the chelator desferrioxamine (DFO). This chelator provides hexadentate coordination to zirconium, leaving two coordination sites available for coordination with, e.g., water molecules, which are relatively labile ligands. The unsaturated coordination of DFO to zirconium has been suggested to result in impaired stability of the complex in vivo and consequently in unwanted bone uptake of 89Zr. Aiming at clinical improvements, we report here on a bifunctional isothiocyanate variant of the octadentate chelator DFO* and the in vitro and in vivo comparison of its 89Zr-DFO*-mAb complex with 89Zr-DFO-mAb.MethodsThe bifunctional chelator DFO*-pPhe-NCS was prepared from previously reported DFO* and p-phenylenediisothiocyanate. Subsequently, trastuzumab was conjugated with either DFO*-pPhe-NCS or commercial DFO-pPhe-NCS and radiolabeled with Zr-89 according to published procedures. In vitro stability experiments were carried out in saline, a histidine/sucrose buffer, and blood serum. The in vivo performance of the chelators was compared in N87 tumor-bearing mice by biodistribution studies and PET imaging.ResultsIn 0.9 % NaCl 89Zr-DFO*-trastuzumab was more stable than 89Zr-DFO-trastuzumab; after 72 h incubation at 2-8 °C 95 % and 58 % intact tracer were left, respectively, while in a histidine-sucrose buffer no difference was observed, both products were ≥ 92 % intact. In vivo uptake at 144 h post injection (p.i.) in tumors, blood, and most normal organs was similar for both conjugates, except for skin, liver, spleen, ileum, and bone. Tumor uptake was 32.59 ± 11.95 and 29.06 ± 8.66 % ID/g for 89Zr-DFO*-trastuzumab and 89Zr-DFO-trastuzumab, respectively. The bone uptake was significantly lower for 89Zr-DFO*-trastuzumab compared to 89Zr-DFO-trastuzumab. At 144 h p.i. for 89Zr-DFO*-trastuzumab and 89Zr-DFO-trastuzumab, the uptake in sternum was 0.92 ± 0.16 and 3.33 ± 0.32 % ID/g, in femur 0.78 ± 0.11 and 3.85, ± 0.80 and in knee 1.38 ± 0.23 and 8.20 ± 2.94 % ID/g, respectively. The uptake in bone decreased from 24 h to 144 h p.i. about two fold for the DFO* conjugate, while it increased about two fold for the DFO conjugate.ConclusionsZr-DFO*-trastuzumab showed superior in vitro stability and in vivo performance when compared to 89Zr-DFO-trastuzumab. This makes the new octadentate DFO* chelator a candidate successor of DFO for future clinical 89Zr-immuno-PET. More... »

PAGES

286-295

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00259-016-3499-x

DOI

http://dx.doi.org/10.1007/s00259-016-3499-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1045664701

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27573793


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chelating Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deferoxamine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Stability", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Isotope Labeling", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Nude", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms, Experimental", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organ Specificity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radioisotopes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Reproducibility of Results", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sensitivity and Specificity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Distribution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Zirconium", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vugts", 
        "givenName": "Danielle J.", 
        "id": "sg:person.0665425270.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665425270.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Klaver", 
        "givenName": "Chris", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sewing", 
        "givenName": "Claudia", 
        "id": "sg:person.0735067024.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735067024.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Poot", 
        "givenName": "Alex J.", 
        "id": "sg:person.01070325626.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070325626.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adamzek", 
        "givenName": "Kevin", 
        "id": "sg:person.016110216521.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016110216521.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Chemistry, University of Zurich, Zurich, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.7400.3", 
          "name": [
            "Department of Chemistry, University of Zurich, Zurich, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huegli", 
        "givenName": "Seraina", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Chemistry, University of Zurich, Zurich, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.7400.3", 
          "name": [
            "Department of Chemistry, University of Zurich, Zurich, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mari", 
        "givenName": "Cristina", 
        "id": "sg:person.01325726600.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325726600.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Visser", 
        "givenName": "Gerard W. M.", 
        "id": "sg:person.013707211632.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013707211632.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Radiopharmaceutical Chemistry, University of Basel Hospital, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.410567.1", 
          "name": [
            "Division of Radiopharmaceutical Chemistry, University of Basel Hospital, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Valverde", 
        "givenName": "Ibai E.", 
        "id": "sg:person.01224225567.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224225567.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Chemistry, University of Zurich, Zurich, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.7400.3", 
          "name": [
            "Department of Chemistry, University of Zurich, Zurich, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gasser", 
        "givenName": "Gilles", 
        "id": "sg:person.0614137050.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614137050.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ludwig Boltzmann Institute for Applied Diagnostics, General Hospital of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.411904.9", 
          "name": [
            "ETH Zurich, Institute of Pharmaceutical Sciences, Vladimir-Prelog Weg 4, CH-8093, Zurich, Switzerland", 
            "Ludwig Boltzmann Institute for Applied Diagnostics, General Hospital of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mindt", 
        "givenName": "Thomas L.", 
        "id": "sg:person.01361130701.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361130701.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.16872.3a", 
          "name": [
            "Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Dongen", 
        "givenName": "Guus A. M. S.", 
        "id": "sg:person.0732223564.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732223564.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00259-009-1263-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005085942", 
          "https://doi.org/10.1007/s00259-009-1263-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13550-015-0098-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048807169", 
          "https://doi.org/10.1186/s13550-015-0098-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nprot.2013.054", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048328786", 
          "https://doi.org/10.1038/nprot.2013.054"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd4255", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037255057", 
          "https://doi.org/10.1038/nrd4255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nprot.2010.13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015342974", 
          "https://doi.org/10.1038/nprot.2010.13"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-08-30", 
    "datePublishedReg": "2016-08-30", 
    "description": "PurposeAll clinical 89Zr-immuno-PET studies are currently performed with the chelator desferrioxamine (DFO). This chelator provides hexadentate coordination to zirconium, leaving two coordination sites available for coordination with, e.g., water molecules, which are relatively labile ligands. The unsaturated coordination of DFO to zirconium has been suggested to result in impaired stability of the complex in vivo and consequently in unwanted bone uptake of 89Zr. Aiming at clinical improvements, we report here on a bifunctional isothiocyanate variant of the octadentate chelator DFO* and the in vitro and in vivo comparison of its 89Zr-DFO*-mAb complex with 89Zr-DFO-mAb.MethodsThe bifunctional chelator DFO*-pPhe-NCS was prepared from previously reported DFO* and p-phenylenediisothiocyanate. Subsequently, trastuzumab was conjugated with either DFO*-pPhe-NCS or commercial DFO-pPhe-NCS and radiolabeled with Zr-89 according to published procedures. In vitro stability experiments were carried out in saline, a histidine/sucrose buffer, and blood serum. The in vivo performance of the chelators was compared in N87 tumor-bearing mice by biodistribution studies and PET imaging.ResultsIn 0.9\u00a0% NaCl 89Zr-DFO*-trastuzumab was more stable than 89Zr-DFO-trastuzumab; after 72\u00a0h incubation at 2-8\u00a0\u00b0C 95\u00a0% and 58\u00a0% intact tracer were left, respectively, while in a histidine-sucrose buffer no difference was observed, both products were\u2009\u2265\u200992\u00a0% intact. In vivo uptake at 144\u00a0h post injection (p.i.) in tumors, blood, and most normal organs was similar for both conjugates, except for skin, liver, spleen, ileum, and bone. Tumor uptake was 32.59\u2009\u00b1\u200911.95 and 29.06\u2009\u00b1\u20098.66\u00a0% ID/g for 89Zr-DFO*-trastuzumab and 89Zr-DFO-trastuzumab, respectively. The bone uptake was significantly lower for 89Zr-DFO*-trastuzumab compared to 89Zr-DFO-trastuzumab. At 144\u00a0h p.i. for 89Zr-DFO*-trastuzumab and 89Zr-DFO-trastuzumab, the uptake in sternum was 0.92\u2009\u00b1\u20090.16 and 3.33\u2009\u00b1\u20090.32\u00a0% ID/g, in femur 0.78\u2009\u00b1\u20090.11 and 3.85,\u2009\u00b1\u20090.80 and in knee 1.38\u2009\u00b1\u20090.23 and 8.20\u2009\u00b1\u20092.94\u00a0% ID/g, respectively. The uptake in bone decreased from 24\u00a0h to 144\u00a0h p.i. about two fold for the DFO* conjugate, while it increased about two fold for the DFO conjugate.ConclusionsZr-DFO*-trastuzumab showed superior in vitro stability and in vivo performance when compared to 89Zr-DFO-trastuzumab. This makes the new octadentate DFO* chelator a candidate successor of DFO for future clinical 89Zr-immuno-PET.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00259-016-3499-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5234086", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "ID/", 
      "bone uptake", 
      "chelator desferrioxamine", 
      "tumor-bearing mice", 
      "h post injection", 
      "clinical improvement", 
      "trastuzumab", 
      "tumor uptake", 
      "normal organs", 
      "biodistribution studies", 
      "post injection", 
      "intact tracer", 
      "PET imaging", 
      "desferrioxamine", 
      "vivo comparison", 
      "blood serum", 
      "Zr-89", 
      "impaired stability", 
      "bifunctional chelator", 
      "h incubation", 
      "bone", 
      "vivo", 
      "MAB complexes", 
      "chelators", 
      "uptake", 
      "vivo performance", 
      "PET", 
      "spleen", 
      "ileum", 
      "tumors", 
      "mice", 
      "liver", 
      "blood", 
      "serum", 
      "saline", 
      "mAbs", 
      "p-phenylenediisothiocyanate", 
      "sternum", 
      "skin", 
      "injection", 
      "histidine/", 
      "organs", 
      "study", 
      "imaging", 
      "conjugates", 
      "folds", 
      "incubation", 
      "differences", 
      "variants", 
      "comparison", 
      "procedure", 
      "improvement", 
      "tracer", 
      "sites", 
      "coordination", 
      "ligands", 
      "buffer", 
      "molecules", 
      "NCS", 
      "complexes", 
      "products", 
      "stability experiments", 
      "experiments", 
      "performance", 
      "stability", 
      "hexadentate coordination", 
      "labile ligands", 
      "successor", 
      "unsaturated coordination", 
      "zirconium", 
      "coordination sites", 
      "water molecules"
    ], 
    "name": "Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET", 
    "pagination": "286-295", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1045664701"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00259-016-3499-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27573793"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00259-016-3499-x", 
      "https://app.dimensions.ai/details/publication/pub.1045664701"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_702.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00259-016-3499-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3499-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3499-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3499-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-016-3499-x'


 

This table displays all metadata directly associated to this object as RDF triples.

317 TRIPLES      22 PREDICATES      122 URIs      109 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00259-016-3499-x schema:about N0047ba365be244bfa61ccc13b504d98f
2 N08005242896b42d9b21fbd4178bb2b18
3 N08aad582e04143829ad0e2eea36fbec0
4 N173104dc5c6c400681e3d201a4403bdc
5 N342ea864ab9d4382bb4eb9b6ddaedc8c
6 N4903b1f789b04557bf26d2345c4612eb
7 N60ce94cd3e0745a7ae1806f173c8bc23
8 N61d728b66c51423593ea86db573ae816
9 N75b8089a93ae4555a5e10a3152d917f5
10 N7859da34e6c548ce94e9a08d2060681c
11 N862ae8c98afc48a2ba52a3bb4296c135
12 N87ced8014a214a2a97d9ad13704fed29
13 Na065a90625b84326a58c56f28fc723e3
14 Na0be009455b14e7d8a1d05349b786d57
15 Nc3b505190f7942ea80413b35af57298c
16 Nc753ad7297e849889fc0b1ee61826c96
17 Ncb9ad155dabd408d85adaa58c7fbd25a
18 Ne7d569b5f7a24f939bf7d522d7a3c393
19 Nf10304a37b2d44648adadf2e45822f4f
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N46a1d61dfdca4904a446a50b78d654c5
23 schema:citation sg:pub.10.1007/s00259-009-1263-1
24 sg:pub.10.1038/nprot.2010.13
25 sg:pub.10.1038/nprot.2013.054
26 sg:pub.10.1038/nrd4255
27 sg:pub.10.1186/s13550-015-0098-y
28 schema:datePublished 2016-08-30
29 schema:datePublishedReg 2016-08-30
30 schema:description PurposeAll clinical 89Zr-immuno-PET studies are currently performed with the chelator desferrioxamine (DFO). This chelator provides hexadentate coordination to zirconium, leaving two coordination sites available for coordination with, e.g., water molecules, which are relatively labile ligands. The unsaturated coordination of DFO to zirconium has been suggested to result in impaired stability of the complex in vivo and consequently in unwanted bone uptake of 89Zr. Aiming at clinical improvements, we report here on a bifunctional isothiocyanate variant of the octadentate chelator DFO* and the in vitro and in vivo comparison of its 89Zr-DFO*-mAb complex with 89Zr-DFO-mAb.MethodsThe bifunctional chelator DFO*-pPhe-NCS was prepared from previously reported DFO* and p-phenylenediisothiocyanate. Subsequently, trastuzumab was conjugated with either DFO*-pPhe-NCS or commercial DFO-pPhe-NCS and radiolabeled with Zr-89 according to published procedures. In vitro stability experiments were carried out in saline, a histidine/sucrose buffer, and blood serum. The in vivo performance of the chelators was compared in N87 tumor-bearing mice by biodistribution studies and PET imaging.ResultsIn 0.9 % NaCl 89Zr-DFO*-trastuzumab was more stable than 89Zr-DFO-trastuzumab; after 72 h incubation at 2-8 °C 95 % and 58 % intact tracer were left, respectively, while in a histidine-sucrose buffer no difference was observed, both products were ≥ 92 % intact. In vivo uptake at 144 h post injection (p.i.) in tumors, blood, and most normal organs was similar for both conjugates, except for skin, liver, spleen, ileum, and bone. Tumor uptake was 32.59 ± 11.95 and 29.06 ± 8.66 % ID/g for 89Zr-DFO*-trastuzumab and 89Zr-DFO-trastuzumab, respectively. The bone uptake was significantly lower for 89Zr-DFO*-trastuzumab compared to 89Zr-DFO-trastuzumab. At 144 h p.i. for 89Zr-DFO*-trastuzumab and 89Zr-DFO-trastuzumab, the uptake in sternum was 0.92 ± 0.16 and 3.33 ± 0.32 % ID/g, in femur 0.78 ± 0.11 and 3.85, ± 0.80 and in knee 1.38 ± 0.23 and 8.20 ± 2.94 % ID/g, respectively. The uptake in bone decreased from 24 h to 144 h p.i. about two fold for the DFO* conjugate, while it increased about two fold for the DFO conjugate.ConclusionsZr-DFO*-trastuzumab showed superior in vitro stability and in vivo performance when compared to 89Zr-DFO-trastuzumab. This makes the new octadentate DFO* chelator a candidate successor of DFO for future clinical 89Zr-immuno-PET.
31 schema:genre article
32 schema:inLanguage en
33 schema:isAccessibleForFree true
34 schema:isPartOf N089f5eb217334dffa27ea84aedefb8f1
35 Nbd4741a3026b4d738b06cbffa5020d1d
36 sg:journal.1297401
37 schema:keywords ID/
38 MAB complexes
39 NCS
40 PET
41 PET imaging
42 Zr-89
43 bifunctional chelator
44 biodistribution studies
45 blood
46 blood serum
47 bone
48 bone uptake
49 buffer
50 chelator desferrioxamine
51 chelators
52 clinical improvement
53 comparison
54 complexes
55 conjugates
56 coordination
57 coordination sites
58 desferrioxamine
59 differences
60 experiments
61 folds
62 h incubation
63 h post injection
64 hexadentate coordination
65 histidine/
66 ileum
67 imaging
68 impaired stability
69 improvement
70 incubation
71 injection
72 intact tracer
73 labile ligands
74 ligands
75 liver
76 mAbs
77 mice
78 molecules
79 normal organs
80 organs
81 p-phenylenediisothiocyanate
82 performance
83 post injection
84 procedure
85 products
86 saline
87 serum
88 sites
89 skin
90 spleen
91 stability
92 stability experiments
93 sternum
94 study
95 successor
96 tracer
97 trastuzumab
98 tumor uptake
99 tumor-bearing mice
100 tumors
101 unsaturated coordination
102 uptake
103 variants
104 vivo
105 vivo comparison
106 vivo performance
107 water molecules
108 zirconium
109 schema:name Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET
110 schema:pagination 286-295
111 schema:productId N3d4f4d381baf431f88de7caaa10afa75
112 Nc4db56d61b0c45cd9f8065e2867150a8
113 Nfa6c8d862a96465681910d3068fa68e8
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045664701
115 https://doi.org/10.1007/s00259-016-3499-x
116 schema:sdDatePublished 2022-05-20T07:32
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher Nf2c0082389954a47830bf59aa7541b32
119 schema:url https://doi.org/10.1007/s00259-016-3499-x
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N0047ba365be244bfa61ccc13b504d98f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Radiopharmaceuticals
125 rdf:type schema:DefinedTerm
126 N08005242896b42d9b21fbd4178bb2b18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Drug Stability
128 rdf:type schema:DefinedTerm
129 N089f5eb217334dffa27ea84aedefb8f1 schema:issueNumber 2
130 rdf:type schema:PublicationIssue
131 N08aad582e04143829ad0e2eea36fbec0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Isotope Labeling
133 rdf:type schema:DefinedTerm
134 N0f4c42bc288c4e97ae8835fb5cfd2b1c rdf:first N7e7cd7df55da4741953f6176f2458c7f
135 rdf:rest Na78233f13f244b42ae9b9a33f9c02324
136 N173104dc5c6c400681e3d201a4403bdc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Zirconium
138 rdf:type schema:DefinedTerm
139 N2a02251e776b4ab2b21eb66e5d87fd36 rdf:first sg:person.01361130701.28
140 rdf:rest Nafe33b334a894542810365d79495a7e3
141 N3122af37a67241d0aae52784eef8bfca rdf:first sg:person.01070325626.43
142 rdf:rest N9e04eea173ed460881b0d02e22587034
143 N342ea864ab9d4382bb4eb9b6ddaedc8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Mice
145 rdf:type schema:DefinedTerm
146 N3d4f4d381baf431f88de7caaa10afa75 schema:name dimensions_id
147 schema:value pub.1045664701
148 rdf:type schema:PropertyValue
149 N46a1d61dfdca4904a446a50b78d654c5 rdf:first sg:person.0665425270.49
150 rdf:rest N0f4c42bc288c4e97ae8835fb5cfd2b1c
151 N4903b1f789b04557bf26d2345c4612eb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Reproducibility of Results
153 rdf:type schema:DefinedTerm
154 N60ce94cd3e0745a7ae1806f173c8bc23 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Tissue Distribution
156 rdf:type schema:DefinedTerm
157 N61d728b66c51423593ea86db573ae816 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Neoplasms, Experimental
159 rdf:type schema:DefinedTerm
160 N75b8089a93ae4555a5e10a3152d917f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Organ Specificity
162 rdf:type schema:DefinedTerm
163 N7859da34e6c548ce94e9a08d2060681c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Mice, Nude
165 rdf:type schema:DefinedTerm
166 N7e7cd7df55da4741953f6176f2458c7f schema:affiliation grid-institutes:grid.16872.3a
167 schema:familyName Klaver
168 schema:givenName Chris
169 rdf:type schema:Person
170 N862ae8c98afc48a2ba52a3bb4296c135 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Animals
172 rdf:type schema:DefinedTerm
173 N87ced8014a214a2a97d9ad13704fed29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Trastuzumab
175 rdf:type schema:DefinedTerm
176 N8b60e1be01c04cd382c0bd1df69fa286 rdf:first sg:person.01325726600.74
177 rdf:rest N96a22f53cd514152ac07e644131afa9c
178 N96a22f53cd514152ac07e644131afa9c rdf:first sg:person.013707211632.52
179 rdf:rest Nba79390f0cd2483e9c121b568cd89bf0
180 N9aa6b73418ab4a21889a9930417f7160 rdf:first Naca1c784d645450e850894694b13c3c4
181 rdf:rest N8b60e1be01c04cd382c0bd1df69fa286
182 N9e04eea173ed460881b0d02e22587034 rdf:first sg:person.016110216521.65
183 rdf:rest N9aa6b73418ab4a21889a9930417f7160
184 Na035a6b7910e43799566be0b47e4ddfa rdf:first sg:person.0614137050.30
185 rdf:rest N2a02251e776b4ab2b21eb66e5d87fd36
186 Na065a90625b84326a58c56f28fc723e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Radioisotopes
188 rdf:type schema:DefinedTerm
189 Na0be009455b14e7d8a1d05349b786d57 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Chelating Agents
191 rdf:type schema:DefinedTerm
192 Na78233f13f244b42ae9b9a33f9c02324 rdf:first sg:person.0735067024.26
193 rdf:rest N3122af37a67241d0aae52784eef8bfca
194 Naca1c784d645450e850894694b13c3c4 schema:affiliation grid-institutes:grid.7400.3
195 schema:familyName Huegli
196 schema:givenName Seraina
197 rdf:type schema:Person
198 Nafe33b334a894542810365d79495a7e3 rdf:first sg:person.0732223564.35
199 rdf:rest rdf:nil
200 Nba79390f0cd2483e9c121b568cd89bf0 rdf:first sg:person.01224225567.60
201 rdf:rest Na035a6b7910e43799566be0b47e4ddfa
202 Nbd4741a3026b4d738b06cbffa5020d1d schema:volumeNumber 44
203 rdf:type schema:PublicationVolume
204 Nc3b505190f7942ea80413b35af57298c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Deferoxamine
206 rdf:type schema:DefinedTerm
207 Nc4db56d61b0c45cd9f8065e2867150a8 schema:name doi
208 schema:value 10.1007/s00259-016-3499-x
209 rdf:type schema:PropertyValue
210 Nc753ad7297e849889fc0b1ee61826c96 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Positron-Emission Tomography
212 rdf:type schema:DefinedTerm
213 Ncb9ad155dabd408d85adaa58c7fbd25a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Cell Line, Tumor
215 rdf:type schema:DefinedTerm
216 Ne7d569b5f7a24f939bf7d522d7a3c393 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Sensitivity and Specificity
218 rdf:type schema:DefinedTerm
219 Nf10304a37b2d44648adadf2e45822f4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Female
221 rdf:type schema:DefinedTerm
222 Nf2c0082389954a47830bf59aa7541b32 schema:name Springer Nature - SN SciGraph project
223 rdf:type schema:Organization
224 Nfa6c8d862a96465681910d3068fa68e8 schema:name pubmed_id
225 schema:value 27573793
226 rdf:type schema:PropertyValue
227 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
228 schema:name Medical and Health Sciences
229 rdf:type schema:DefinedTerm
230 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
231 schema:name Clinical Sciences
232 rdf:type schema:DefinedTerm
233 sg:grant.5234086 http://pending.schema.org/fundedItem sg:pub.10.1007/s00259-016-3499-x
234 rdf:type schema:MonetaryGrant
235 sg:journal.1297401 schema:issn 1619-7070
236 1619-7089
237 schema:name European Journal of Nuclear Medicine and Molecular Imaging
238 schema:publisher Springer Nature
239 rdf:type schema:Periodical
240 sg:person.01070325626.43 schema:affiliation grid-institutes:grid.16872.3a
241 schema:familyName Poot
242 schema:givenName Alex J.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070325626.43
244 rdf:type schema:Person
245 sg:person.01224225567.60 schema:affiliation grid-institutes:grid.410567.1
246 schema:familyName Valverde
247 schema:givenName Ibai E.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224225567.60
249 rdf:type schema:Person
250 sg:person.01325726600.74 schema:affiliation grid-institutes:grid.7400.3
251 schema:familyName Mari
252 schema:givenName Cristina
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01325726600.74
254 rdf:type schema:Person
255 sg:person.01361130701.28 schema:affiliation grid-institutes:grid.411904.9
256 schema:familyName Mindt
257 schema:givenName Thomas L.
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361130701.28
259 rdf:type schema:Person
260 sg:person.013707211632.52 schema:affiliation grid-institutes:grid.16872.3a
261 schema:familyName Visser
262 schema:givenName Gerard W. M.
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013707211632.52
264 rdf:type schema:Person
265 sg:person.016110216521.65 schema:affiliation grid-institutes:grid.16872.3a
266 schema:familyName Adamzek
267 schema:givenName Kevin
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016110216521.65
269 rdf:type schema:Person
270 sg:person.0614137050.30 schema:affiliation grid-institutes:grid.7400.3
271 schema:familyName Gasser
272 schema:givenName Gilles
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614137050.30
274 rdf:type schema:Person
275 sg:person.0665425270.49 schema:affiliation grid-institutes:grid.16872.3a
276 schema:familyName Vugts
277 schema:givenName Danielle J.
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665425270.49
279 rdf:type schema:Person
280 sg:person.0732223564.35 schema:affiliation grid-institutes:grid.16872.3a
281 schema:familyName van Dongen
282 schema:givenName Guus A. M. S.
283 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732223564.35
284 rdf:type schema:Person
285 sg:person.0735067024.26 schema:affiliation grid-institutes:grid.16872.3a
286 schema:familyName Sewing
287 schema:givenName Claudia
288 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735067024.26
289 rdf:type schema:Person
290 sg:pub.10.1007/s00259-009-1263-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005085942
291 https://doi.org/10.1007/s00259-009-1263-1
292 rdf:type schema:CreativeWork
293 sg:pub.10.1038/nprot.2010.13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015342974
294 https://doi.org/10.1038/nprot.2010.13
295 rdf:type schema:CreativeWork
296 sg:pub.10.1038/nprot.2013.054 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048328786
297 https://doi.org/10.1038/nprot.2013.054
298 rdf:type schema:CreativeWork
299 sg:pub.10.1038/nrd4255 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037255057
300 https://doi.org/10.1038/nrd4255
301 rdf:type schema:CreativeWork
302 sg:pub.10.1186/s13550-015-0098-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1048807169
303 https://doi.org/10.1186/s13550-015-0098-y
304 rdf:type schema:CreativeWork
305 grid-institutes:grid.16872.3a schema:alternateName Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands
306 schema:name Department of Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan 1085, loc. Radionuclide Center, 1081HV, Amsterdam, The Netherlands
307 rdf:type schema:Organization
308 grid-institutes:grid.410567.1 schema:alternateName Division of Radiopharmaceutical Chemistry, University of Basel Hospital, Basel, Switzerland
309 schema:name Division of Radiopharmaceutical Chemistry, University of Basel Hospital, Basel, Switzerland
310 rdf:type schema:Organization
311 grid-institutes:grid.411904.9 schema:alternateName Ludwig Boltzmann Institute for Applied Diagnostics, General Hospital of Vienna, Vienna, Austria
312 schema:name ETH Zurich, Institute of Pharmaceutical Sciences, Vladimir-Prelog Weg 4, CH-8093, Zurich, Switzerland
313 Ludwig Boltzmann Institute for Applied Diagnostics, General Hospital of Vienna, Vienna, Austria
314 rdf:type schema:Organization
315 grid-institutes:grid.7400.3 schema:alternateName Department of Chemistry, University of Zurich, Zurich, Switzerland
316 schema:name Department of Chemistry, University of Zurich, Zurich, Switzerland
317 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...